These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The use of procarbazine hydrochloride versus cyclophosphamide in donor pretreatment in cadaveric renal transplantation.
    Author: Zincke H, Woods JE, Roses J, Kimbler RW.
    Journal: Mayo Clin Proc; 1976 Nov; 51(11):693-6. PubMed ID: 792579.
    Abstract:
    During a prospective study, 13 patients received renal transplants from cadaveric donors whose hearts beat up to the time of their death. These donors were pretreated with cyclophosphamide-methylprednisolone (group A) or methylprednisolone-procarbazine hydrochloride (group B). After a minimum follow-up of 12 months, all grafts in group A but only one graft in group B survived. On the basis of this small experience, the combination of cyclophosphamide and methylprednisolone seems to be superior to that of methylprednisolone and procarbazine hydrochloride in reducing allograft immunogenicity. In order to achieve longer survival of the graft in the recipient, pretreatment with procarbazine hydrochloride has been discontinued. Pretreatment of the potential cadaveric allograft donor with cyclophosphamide and methylprednisolone is being continued at our institution.
    [Abstract] [Full Text] [Related] [New Search]